# A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

> **NCT07432568** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **OTHER:** Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin
- **DRUG:** Lenvatinib
- **DRUG:** PD-1 Inhibitor

## Key facts

- **NCT ID:** NCT07432568
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2032-06-09
- **Final completion:** 2032-08-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432568, "A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07432568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*